AMRI Announces Five-Year Extension of API Supply Agreement with Shire
News Oct 23, 2012
AMRI has announced that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing Inc., whose parent company, Shire plc, is a global company that focuses its business on behavioral health, gastro intestinal diseases, rare diseases and regenerative medicine.
The agreement extends a previously existing agreement between the two companies. The terms of the agreement are confidential.
“We are pleased to extend this agreement with Shire,” said Thomas E. D’Ambra, Ph.D., Chairman, President and Chief Executive Officer of AMRI.
D’Ambra continued, “Our partnership lays the groundwork for AMRI to be considered by Shire for future development and manufacturing opportunities.”
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018